TRUE Private Wealth Advisors’s Intellia Therapeutics NTLA Stock Holding History

TRUE Private Wealth Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-77	Closed	-$1K	–	776
2019 Q4	$1K	Buy	+77	New	+$1.07K	﹤0.01%	777
2019 Q3	–	Sell	-77	Closed	-$1K	–	553
2019 Q2	$1K	Buy	+77	New	+$1.21K	﹤0.01%	765
2018 Q4	–	Sell	-15,011	Closed	-$430K	–	695
2018 Q3	$430K	Buy	15,011 +1,715	+13%	+$49.9K	0.06%	183
2018 Q2	$363K	Buy	13,296 +2,533	+24%	+$61.4K	0.06%	193
2018 Q1	$226K	Buy	+10,763	New	+$265K	0.04%	211

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRUE Private Wealth Advisors's NTLA Position: Q1 2020 in Review

TRUE Private Wealth Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2020, closing a stake of 77 shares — an estimated $1K sold.

TRUE Private Wealth Advisors first reported a position in NTLA in Q1 2018 and held it in 5 quarters. The position peaked at $430K in Q3 2018. 140 funds tracked by Wall St. Rank hold NTLA as of Q1 2020.

TRUE Private Wealth Advisors reported no remaining Intellia Therapeutics position as of Q1 2020 after selling out during the quarter.
TRUE Private Wealth Advisors sold 77 Intellia Therapeutics shares in Q1 2020, an estimated $1K.
TRUE Private Wealth Advisors first reported a position in Intellia Therapeutics in Q1 2018 and held it in 5 quarters.
TRUE Private Wealth Advisors's Intellia Therapeutics position peaked at $430K in Q3 2018.
140 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2020.

Based on TRUE Private Wealth Advisors's 13F filing for Q1 2020, filed 20 Apr 2020.